FXR
Agonists
The Bile Acid Nuclear Receptor.
- Disease
- Metabolic
- Status
- Clinical
- Licensed
- Intercept Pharmaceuticals
The Target
The nuclear receptor FXR is a bile acid receptor located in the liver, intestine, kidney, and adipose tissue. Upon activation FXR acts as a regulator of many biological processes, including: bile acid metabolism, inflammation, fibrosis, glucose metabolism, and lipid metabolism. FXR is thus an attractive target for new drugs to treat dyslipidemia and liver disorders, such as NAFLD and hypertriglyceridemia.
Our Research
A FXR agonist identified by Tes Pharma is currently being evaluated in Phase 1 clinical trials. The compound appears to be a more selective FXR agonist than Obeticholic Acid (OCA) and has shown potential anti-fibrotic and anti-inflammatory effects in animal models.